eli lilly sues four telehealth compounding glp-1 companies selling alternative versions of its weight loss drug Eli Lilly Sues 4 GLP-1

GHK-Cu and Anti-Inflammatory Pathway Research In murine lipopolysaccharide-induced acute lung injury models, GHK-Cu reduced inflammatory cell infiltration, suppressed NF-B and p38 MAPK activation, and lowered TNF-alpha and IL-6 levels compared to untreated groups findings of interest in inflammatory pathway research

HPLC establishes concentration and purity by separating blend constituents, while mass spectrometry confirms the precise molecular identity of each peptide

In cellular assays measuring cAMP accumulation, orforglipron achieves approximately 60-80% of the maximal response produced by GLP-1, depending on the assay system and receptor expression levels

Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, et al

And I'm just laughing because I was talking with a friend who does do peptides

The loss of exclusivity for these drugs will likely open the market for generics, impacting Pfizers overall sales revenue